Three months after announcing a breakthrough in research, the Zydus Group on Tuesday announced the launch of Lipaglyn, a novel drug targeted at diabetes not controlled by statins alone.

This is expected to meet a healthcare need for treating diabetic dyslipidemia and hypertriglyceridemia in Type II diabetes. Lipaglyn will be available across India and can be prescribed by cardiologists, diabetologists and general physicians. The therapy is priced at Rs 25.90 per tablet, according to a company release here.

The therapy is being marketed by Zydus Discovery, a new division launched to market the original research products of the group’s research pipeline, said Pankaj R. Patel, Chairman and Managing Director, Zydus Cadila.

Globally, three out of every four patients suffering from diabetes also suffer from dyslipidemia. India has a population of nearly 65 million diabetics and 77 million pre-diabetics and of this, an estimated 55 million people currently suffer from diabetic dyslipidemia.

Discovered by the Zydus Research Centre, Lipaglyn has been developed by a team of 400 research scientists at ZRC. Zydus Discovery will offer a dedicated Lipaglyn support programme to patients and caregivers. The programme will provide counselling and support through toll-free helpline numbers.

(This article was published on September 17, 2013)
XThese are links to The Hindu Business Line suggested by Outbrain, which may or may not be relevant to the other content on this page. You can read Outbrain's privacy and cookie policy here.